Clinical diagnostics & drug development
Translating microbiome knowledge into actionable information
Bio-Me’s qPCR-based PMP™ technology supports drug developers in their development pipeline and clinical researchers and pharma in diagnostic test development.
Applications
Where PMP™ fits in your programme
Drug developers
LBP production quality control
Quality control of production runs of live biotherapeutic products (LBPs).
Drug developers
Clinical trial stratification
Stratify patient populations in clinical trials.
Drug developers
LBP engraftment monitoring
Monitor engraftment of live biotherapeutic products.
Diagnostic test development
Patient profiling
Accurately profile patients participating in clinical trials for tests on disease detection, recurrence or response to a specific drug.
Biomarker research
Discovery and validation
Combine PMP™ with Bio-Me’s access to the HUNT4 biobank through collaboration.
PMP™ is offered as an analysis service supporting research and development. It is not presented here as a regulatory-approved diagnostic product.
Our advantages
Speed and precision for clinical studies
- High throughput — hundreds of samples analysed simultaneously
- Highly reproducible
- Short turnaround — results ready in 1–3 days from sample arrival
- Absolute quantification — output is number of genomes per ng of DNA in the analysis
- Ready-to-use results — no bioinformatics steps needed on your side
“We found that the PMP™ quantitative PCR method was a useful tool to identify important microbial biomarkers in a large population cohort.”
“The PMP™ technology made it possible for us to quickly determine subclasses of IBD for the first time and identify optimal treatment regime for adolescents.”
Experience across academic and commercial collaborations
Bio-Me has extensive experience in optimising targeted microbiome solutions through collaborations with several academic and commercial entities.
Let’s discuss your microbiome project.
Tell us about your research question, application or analysis needs.